Genetic landscape of salivary duct carcinoma.

Slides:

Advertisements

Similar presentations

VogelsteinScience15Apr13.ppt Updated: April 15, 2013 Why Is Cancer Therapy Such a Difficult and Often Intractable Effort? Cancer Genome Landscapes. Science,

Advertisements

Hairy Cell Leukemia Variant Has Similar Survival to Classical Disease Despite Poorer Responses to Initial Therapy: A 30-Year Experience from Memorial Sloan.

Samsung Genome Institute Samsung Medical Center

Molecular Dissection of Complete Response to Receptor Tyrosine Kinase Inhibition in Type II Papillary Renal Cell Carcinoma Matti Annala, Lucia Nappi,

Clinical trial matching.

Summary of genetic alterations in resistant biopsies among patients progressing on ceritinib or alectinib. Summary of genetic alterations in resistant.

The Genomics of Cancer and Molecular Testing:

Figure 4 Possible combination therapies CDK4/6 inhibitors

Figure 6 Common signalling mechanisms, pathways,

Why Is Cancer Therapy Such a Difficult and Often Intractable Effort?

WES detects a limited number of clinically targetable alterations in patients with advanced cancer. WES detects a limited number of clinically targetable.

Figure 1 Therapeutic targeting of the B-cell receptor (BCR)

Volume 27, Issue 3, Pages (March 2015)

Why Is Cancer Therapy Such a Difficult and Often Intractable Effort?

Tyrosine Kinase Inhibitors in Clinical Practice: Patient Selection

Ovarian cancer cells harbour numerous copy number alterations unlinked to drug‐induced cell death Ovarian cancer cells harbour numerous copy number alterations.

Kaplan–Meier survival curves of overall survival (OS) for EGFR mutant lung adenocarcinoma patients who received epidermal growth factor receptor tyrosine.

Characterizing the Killer Colorectal Carcinomas

Patterns of Somatically Acquired Amplifications and Deletions in Apparently Normal Tissues of Ovarian Cancer Patients Leila Aghili, Jasmine Foo, James.

Alterations related to androgen signaling.

Overview of the complex interactions among molecular classifications of TNBC based on genomic, transcriptomic, proteomic, epigenomic, and immune characterization.

Robustness of TRU, Proximal-proliferative (PP), and Proximal-inflammatory (PI) classification. Robustness of TRU, Proximal-proliferative (PP), and Proximal-inflammatory.

Patterns of Somatically Acquired Amplifications and Deletions in Apparently Normal Tissues of Ovarian Cancer Patients Leila Aghili, Jasmine Foo, James.

Landscape of genomic alterations in 444 tumors from 429 patients with mCRPC. Landscape of genomic alterations in 444 tumors from 429 patients with mCRPC.

Kaplan–Meier curves of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) progression-free survival (PFS) for EGFR mutant lung adenocarcinoma.

Fig. 2. Clinically actionable somatic genomic alterations in various tumor types. Clinically actionable somatic genomic alterations in various tumor types.

SiRNA screening identifies genes required for the viability of Pim1-ovexpressing prostate cells. siRNA screening identifies genes required for the viability.

Representative examples of estrogen receptor α and β immunohistochemical expression (top figures) and EGFR mutations (bottom figures) in lung adenocarcinomas.

Association between RB pathway alterations and poor prognosis in early-stage lung adenocarcinoma patients. Association between RB pathway alterations and.

Frequent alterations identified and potential actionability.

X-tile analysis of survival data from the SEER registry reveals a continuous distribution based on tumor size and node number, and a U-shaped distribution.

Protein expression profile in a dasatinib-resistant cell line.

KIT mutations in GISTs. A, amino acid sequence of KIT exon 11 mutations in clinical GIST biopsies. –, amino acids that are deleted; italicized amino acids,

Presentations of thyroid disorders after receiving immune checkpoint inhibition combination therapy or monotherapy. Presentations of thyroid disorders.

Study overview. Study overview. A, Schematic illustrating clinical trial design and the nature and number of tissue specimens available for downstream.

Tamoxifen-treated patients.

Overview of TIMER modules on the website.

Antitumor activity of AMG 102 in combination with bevacizumab or motesanib. Antitumor activity of AMG 102 in combination with bevacizumab or motesanib.

Somatic mutational rates and survival analysis of IBD-CRC.

The treatment history and genomic landscape of a metastatic carcinoma with an extreme outlier response to combination therapy. The treatment history and.

Targetable alterations and pathways in TNBCs after NAC

Location of common clinically relevant mutations in EGFR

Simplified BRAF signaling network.

Survival risk prediction analysis and application of the metastasis gene signature. Survival risk prediction analysis and application of the metastasis.

Kaplan-Meier survival analysis of p53 mutation in the overall breast tumor series. Kaplan-Meier survival analysis of p53 mutation in the overall breast.

Distribution of FGFR aberrancies in urothelial cancers.

PSMA expression in pre- and posttreatment prostate carcinoma serum.

High-throughput drug screen (HTDS) reveals ARS1620 and PI3K pathway inhibitors synergies and a heterogeneous pattern of RTK synergies. High-throughput.

The long tail of mutational hotspots in cancer.

Prevalence of germline T790M.

Location of the ER mutations and frequencies per cohort.

Mean percentage change from baseline in total IGF-I and the R1507 serum concentration values following a single i.v. administration of R mg/kg (n.

A, Selected 4 quantitative imaging features significantly associated with 3 imaging subtypes, including tumor volume, tumor sphericity, tumor homogeneity.

Global mutational landscape of the 170 lung adenocarcinoma patients (discovery cohort). Global mutational landscape of the 170 lung adenocarcinoma patients.

Molecular definitions of lung adenocarcinoma subtypes.

The best response for target lesions per patient for patients with target lesions assessed at baseline and at least 1 follow-up. The best response for.

DFS and DSS curves according to low, intermediate, and high stromal CD8+ T-cell density in the four different cohorts; A and B, University Hospital of.

RhuαVEGF and rhuαVEGF/paclitaxel mediated growth inhibition in an androgen-independent prostate cancer xenograft model. rhuαVEGF and rhuαVEGF/paclitaxel.

Concordance between the genomic landscape identified by whole-exome sequencing of plasma cfDNA and tumor; DNA and recurrence of KDR/VEGFR2 oncogenic mutations.

Genetic analysis suggests the presence of four clinically relevant groups of histologically defined anaplastic oligodendrogliomas. Genetic analysis suggests.

Identification of RASA1- and NF1-mutated lung cancer cell lines in the CCLE dataset (accessed via the cBioPortal for Cancer Genomics at

Landscape of genomic alterations identified by WES in biopsies of patients with advanced PDAC. Co-mutation plot displaying integrated genomic data for.

Regression analysis showing the positive correlation between number of months since the prior chemotherapy regimen (X axis) and the difference between.

Relative frequencies of FGFR aberrations in non–small cell lung carcinoma. Relative frequencies of FGFR aberrations in non–small cell lung carcinoma. A,

Representative images for different populations of detected cells in prostate cancer patients and five rounds of FISH in a CTC. A, Immunofluorescence image.

PIK3CA somatic mutation and amplification frequency in prostate cancer

Mutational signature analysis of WES data from patients with advanced PDAC. A, Projection of signatures representing four main mutational processes identified.

Driver pathways and key genes in OSCC

Molecular characterization of esophagogastric tumors.

Fig. 1. Schematic description of whole-exome or targeted next-generation sequencing analyses. Schematic description of whole-exome or targeted next-generation.

Presentation transcript:

Genetic landscape of salivary duct carcinoma. Genetic landscape of salivary duct carcinoma. A, number of somatic mutations (top), clinical data (middle), and selected genetic alterations (bottom) in 16 patients with SDC. Androgen sign., androgen signaling; RTKs, receptor tyrosine kinases. *Hotspot mutation, at least 20 cases of the mutation reported in the COSMIC database (cancer.sanger.ac.uk/cosmic). B, most commonly altered genes in cohorts 1 and 2 combined. Mutations and significant CNAs are included. C, percentage of patients with potentially targetable alterations according to the Memorial Sloan Kettering Cancer Center levels of evidence and the specific alterations listed for each category. Ampl., amplification. Martin G. Dalin et al. Clin Cancer Res 2016;22:4623-4633 ©2016 by American Association for Cancer Research